Last reviewed · How we verify
PF-07104091 monotherapy dose expansion (SCLC) — Competitive Intelligence Brief
phase 2
Live · refreshed every 30 min
Target snapshot
PF-07104091 monotherapy dose expansion (SCLC) (pf-07104091-monotherapy-dose-expansion-sclc) — Pfizer Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| PF-07104091 monotherapy dose expansion (SCLC) TARGET | pf-07104091-monotherapy-dose-expansion-sclc | Pfizer Inc. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- PF-07104091 monotherapy dose expansion (SCLC) CI watch — RSS
- PF-07104091 monotherapy dose expansion (SCLC) CI watch — Atom
- PF-07104091 monotherapy dose expansion (SCLC) CI watch — JSON
- PF-07104091 monotherapy dose expansion (SCLC) alone — RSS
Cite this brief
Drug Landscape (2026). PF-07104091 monotherapy dose expansion (SCLC) — Competitive Intelligence Brief. https://druglandscape.com/ci/pf-07104091-monotherapy-dose-expansion-sclc. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab